Kucinska, Malgorzata Skupin-Mrugalska, Paulina Szczolko, Wojciech Sobotta, Lukasz Sciepura, Mateusz Tykarska, Ewa Wierzchowski, Marcin Teubert, Anna Fedoruk-Wyszomirska, Agnieszka Wyszko, Eliza Gdaniec, Maria Kaczmarek, Mariusz Goslinski, Tomasz Mielcarek, Jadwiga Murias, Marek Phthalocyanine Derivatives Possessing 2‑(Morpholin-4-yl)ethoxy Groups As Potential Agents for Photodynamic Therapy Three 2-(morpholin-4-yl)­ethoxy substituted phthalocyanines were synthesized and characterized. Phthalocyanine derivatives revealed moderate to high quantum yields of singlet oxygen production depending on the solvent applied (e.g., in DMF ranging from 0.25 to 0.53). Their photosensitizing potential for photodynamic therapy was investigated in an in vitro model using cancer cell lines. Biological test results were found particularly encouraging for the zinc­(II) phthalocyanine derivative possessing two 2-(morpholin-4-yl)­ethoxy substituents in nonperipheral positions. Cells irradiated for 20 min at 2 mW/cm<sup>2</sup> revealed the lowest IC<sub>50</sub> value at 0.25 μM for prostate cell line (PC3), whereas 1.47 μM was observed for human malignant melanoma (A375) cells. The cytotoxic activity in nonirradiated cells of novel phthalocyanine was found to be very low. Moreover, the cellular uptake, localization, cell cycle, apoptosis through an ELISA assay, and immunochemistry method were investigated in LNCaP cells. Our results showed that the tested photosensitizer possesses very interesting biological activity, depending on experimental conditions. Biological test results;0.25 μ M;nonperipheral positions;cytotoxic activity;LNCaP cells;ELISA assay;PC;novel phthalocyanine;cell cycle;nonirradiated cells;DMF;quantum yields;Potential Agents;Phthalocyanine derivatives;1.47 μ M;singlet oxygen production;20 min;cancer cell lines;photodynamic therapy;prostate cell line;IC 50 value;immunochemistry method 2015-03-12
    https://acs.figshare.com/articles/dataset/Phthalocyanine_Derivatives_Possessing_2_Morpholin_4_yl_ethoxy_Groups_As_Potential_Agents_for_Photodynamic_Therapy/2186716
10.1021/acs.jmedchem.5b00052.s003